Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation: One-Year Data from the Global ETNA-AF Program

Figures

• 

  Figure 1. Patients included in the Global ETNA-AF non-interventional program.

• 

  Figure 2. Edoxaban dosing * at baseline in the Global ETNA-AF non-interventional program. * Edoxaban dose reduction criteria: body weight ≤ 60 mg; creatinine clearance 15–50 mL/min; and concomitant use of certain P-gp inhibitors (ciclosporin, dronedarone, erythromycin, and ketoconazole).

• 

  Figure 3. Proportion of patients receiving a non-recommended dose of edoxaban by (A) CrCl category or (B) body weight. The dashed vertical lines indicate the respective dose-reduction thresholds. The thresholds for dose reduction are CrCl ≤ 50 mL/min and body weight ≤ 60 kg, respectively. p-values are included for the category closest to the dosing threshold vs. the next closest category: CrCl 45–50 mL/min vs. CrCl 40–45 mL/min; CrCl 50–55 mL/min vs. CrCl 55–60 mL/min; body weight 55–60 kg vs. body weight 50–55 kg; body weight 60–65 kg vs. body weight 65–70 kg. CrCl, creatinine clearance.

• 

  Figure 4. Forest plots of hazard ratios (95% CI) for clinical events in (A) patient groups without dose reduction criteria (“Underdosing” vs. recommended dosing) and (B) patient groups that met at least one dose reduction criterion (“Overdosing” vs. recommended dosing). CI, confidence interval; CRNM, clinically relevant non-major; CV, cardiovascular; HR, hazard ratio; ICH, intracranial hemorrhage; ISTH, International Society on Thrombosis and Hemostasis; MI, myocardial infarction; SEE, systemic embolic events; TIA, transient ischemic attack.

• 

  Figure 5. Kaplan–Meier curves for (a) ischemic stroke, (b) major bleeding, and (c) all-cause death in patients without dose reduction criteria (non-recommended 30 mg “underdosing” vs. recommended 60 mg dosing groups) and those who met at least one dose reduction criterion (non-recommended 60 mg “overdosing” vs. recommended 30 mg dosing groups).